Interleukin-7 - Revimmune SAS

Drug Profile

Interleukin-7 - Revimmune SAS

Alternative Names: CYT 107; Glycosylated recombinant human interleukin-7 - Cytheris; IL-7; Recombinant human interleukin-7 - Cytheris; rhIL-7; Second-generation CYT 99 007

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytheris
  • Developer Cognate BioServices; Cytheris; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Revimmune SAS; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The French National Agency for Research on AIDS and Viral Hepatitis
  • Class Antineoplastics; Antivirals; Interleukins
  • Mechanism of Action Immunomodulators; Interleukin 7 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer; Breast cancer; Colorectal cancer; HIV infections; Prostate cancer; Sepsis
  • Clinical Phase Unknown Idiopathic CD4-positive T-lymphocytopenia
  • Discontinued Bone marrow transplant rejection; Hepatitis B; Hepatitis C; Progressive multifocal leukoencephalopathy

Most Recent Events

  • 17 Oct 2017 Revimmune terminates a phase II trial due to failure of supply of test product in Sepsis in France (IM) (SC) (NCT02797431)
  • 15 Mar 2016 Biomarkers information updated
  • 08 Jan 2016 Revimmune, Vanderbilt University School of Medicine and Washington University School of Medicine plan the phase II IRIS-7B for Sepsis in USA (IM) (NCT02640807)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top